The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after two teenage boys receiving the treatment died earlier this year.
Sarepta Didn’t Tell Investors About a Patient Death. Wall Street is Furious.
view original post